Kyverna Therapeutics, Inc.
mivocabtagene autoleucel
stiff person syndrome
Resolved
7days ago
FDA decision · ~ Jun 30, 2026 estimated
What's at stake
The FDA's approval decision on mivocabtagene autoleucel for stiff person syndrome is due ~ Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 16h ago
“Kyverna anticipates submitting its first Biologics License Application (BLA) in the first half of 2026.”